Embed Size (px)
Citation preview
SUPPLEMENTAL MATERIAL
SUPPLEMENTAL FIGURES AND FIGURE LEGENDS
Supplemental Figure I
Supplemental Fig. I Schematic representation of the groups and treatments. One group of E3L and E3L.CETP mice were fed on a normal chow diet supplemented with anacetrapib (3mg/kg/day), evacetrapib (3mg/kg/day) or placebo
for 3 weeks after what the mice were sacrificed for cholesterol efflux measurement, PON-1 activity assay and
lipoprotein fractionation by either NMR and/or FPLC. Another group of E3L and E3L.CETP mice were fed on a high
cholesterol diet supplemented with anacetrapib (3mg/kg/day), evacetrapib (3mg/kg/day) or placebo for 21 weeks
after what the mice were sacrificed and assayed for lipoprotein fractionation by either NMR and/or FPLC, ROS
determination and endothelium dependent vasodilation. The mice on a high cholesterol diet were assayed in the
week 5 and 14 for total cholesterol and triglycerides as described in the Method section.
Supplemental Figure II
Supplemental Fig. II Weight of E3L.CETP mice at baseline (t=0, before starting the treatment) and after the
treatment (t=21 weeks) with 3mg/kg/day anacetrapib (ANA), 3 mg/kg/day evacetrapib (EVA), or placebo (CTRL) on a
high cholesterol diet
weeks 0 3 Normal chow diet
c holesterol efflux measurement/ PON-1 activity
21
vascular function lipoprotein profiling ROS production .
High cholesterol diet
E3L/E3L.CETP mice with 3mg/kg/day
evacetrapib/ anacetrapib/
placebo
CtrlANA
EVA0
10
20
30
body
wei
ght (
g)
t=0t=21
Supplemental Figure IIII
A B
Supplemental Fig. III Triglycerides (A) and cholesterol (B) levels at 21 weeks in E3L.CETP mice fed on a high
cholesterol diet;; n.s.= not significant;; N=9-12
Supplemental Figure IV
A B
Supplemental Fig. IV TG (A) and cholesterol (B) levels measured in plasma of E3L mice treated for 0, 5 and 14 weeks on a high cholesterol diet with 3mg/kg/day anacetrapib (ANA), 3 mg/kg/day evacetrapib (EVA), or placebo
(CTRL);; N=11-13
CtrlANA
EVA0.0
0.5
1.0
1.5
2.0
2.5
Trig
lyce
rides
mM
t0t5t14
CtrlANA
EVA0
5
10
15
Cho
lest
erol
mM
t0t5t14
CTRLANA
EVA0
1
2
3
Trig
lyce
rides
mM
CTRLANA
EVA0
2
4
6
8
10
Cho
lest
erol
mM
*" *" *"
n.s.$
Supplemental Figure V
A B
Supplemental Fig. V FPLC lipoprotein-cholesterol profile of E3L.CETP treated 3mg/kg/day anacetrapib (A) and 3mg/kg/day evacetrapib (B) for 3 weeks on a normal chow diet
Supplemental Figure VI
A B
Supplemental Fig. VI FPLC lipoprotein-triglycerides profile of E3L.CETP mice treated with 3mg/kg/day anacetrapib
(ANA) (A) and 3mg/kg/day evacetrapib (EVA) (B) for 21 weeks on a high cholesterol diet
20 40 60 800.00
0.01
0.02
0.03
0.04
Retention time (min)
AU
ANA-0 weeksANA-3 weeks
20 40 60 800.00
0.01
0.02
0.03
0.04
Retention time (min)
AU
EVA-0 weeksEVA-3 weeksVLDL$
LDL$
HDL$
VLDL$
LDL$
HDL$
20 40 60 800.00
0.05
0.10
0.15
Retention time (min)
AU
ANA-0 weeksANA-21weeks
20 40 60 800.00
0.05
0.10
0.15
Retention time (min)
AU
EVA-0 weeksEVA-21weeks
VLDL$
HDL$
glycerol$
VLDL$
HDL$
glycerol$
Supplemental Figure VII
Supplemental Fig. VII Large HDL particles in pooled serum of E3L.CETP treated with 3mg/kg/day anacetrapib
(ANA), 3 mg/kg/day evacetrapib (EVA), and placebo (CTRL) for 3 weeks on a normal chow diet
SUPPLEMENTAL TABLES Supplemental Table I
Supplemental Table I Analysis of FPLC-derived cholesterol- and triglycerides- lipoprotein profiles for the basal values before the start of treatment with anacetrapib (ANA0) or evacetrapib (EVA0) and after 3 weeks of the treatment with anacetrapib-ANA3
(3mg/kg/day) or evacetrapib –EVA3 (3mg/kg/day) in E3L.CETP mice on a normal chow diet
Supp. Table I
Cholesterol plasma concentration (mM) TG plasma concentration (mM) Total
Cholesterol VLDL-‐‑C LDL-‐‑C HDL-‐‑C TG VLDL-‐‑TG LDL-‐‑TG HDL-‐‑TG Free Glycerol
ANA0 2.58 0.94 0.79 0.85 2.22 0.99 0.28 0.09 8.31
ANA3 2.24 0.75 0.59 0.90 1.72 0.79 0.28 0.07 5.60
EVA0 2.58 0.95 0.73 0.90 2.12 0.91 0.29 0.08 8.14
EVA3 2.35 0.78 0.70 0.87 1.58 0.68 0.27 0.06 5.55
Supplemental Table II
Supplemental Table II. Analysis of FPLC-derived cholesterol- and triglycerides- lipoprotein profiles for the basal values before the start of treatment with anacetrapib (ANA0) or evacetrapib (EVA0) and after 21 weeks of the treatment with anacetrapib-
ANA21 (3mg/kg/day) or evacetrapib –EVA21 (3mg/kg/day) in E3L.CETP mice on a high cholesterol diet
Supp. Table II
Cholesterol plasma concentration (mM) TG plasma concentration (mM)
Total Cholesterol
VLDL-‐‑C LDL-‐‑C HDL-‐‑C TG VLDL-‐‑TG LDL-‐‑TG HDL-‐‑TG
ANA0 4.05 1.66 1.54 0.86 2.43 0.83 0.31 0.07
ANA21 6.60 1.39 0.58 4.62 1.43 0.40 0.12 0.13
EVA0 4.37 1.88 1.63 0.86 2.79 1.01 0.37 0.09
EVA21 8.88 3.65 2.35 2.88 1.41 0.49 0.12 0.12
